Revotek Receives Clearance from the National Health Commission of China for the World First Clinical Trial for 3D Bioprinted Stem Cell Vascular Grafts


    CHENGDU, China, Feb. 21, 2022 /PRNewswire/ -- Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.


    "The clearance marks an important milestone for Revotek. We are excited to advance REVOVAS, our first stem cell 3D bioprinting product for patients with Peripheral Artery Diseases (PADs), and we hope that the upcoming study will serve as validation of our stem cell 3D bio-printing platform as a whole," said Ms Yin Xie, CEO of Revotek, "This initial study will help determine the safety and potential effectiveness of the stem cell 3D biological printing platform, and will mark its place as a new autologous stem-cell-therapy platform to provide regenerative therapies for a range of chronic diseases, reaching patients with various cardiovascular diseases, and many others, with this life-changing therapy. "

    The clearance allows for a clinical study to evaluate the safety of REVOVAS in individuals with PADs. Revotek anticipates starting the clinical study in Q2 2022.

    About Revotek

    Revotek, established in 2014, provides life-saving stem cell technologies that enable the delivery of fully personalized healthcare solutions. Revotek has developed the world's first Biosynsphere technology, a universal bio-ink that allows scaffold-free bioprinting. The 3D blood vessel bioprinter and bone repairing devices are derived and developed based on this technology, which is of great value in clinical applications. Revotek's technologies have been recognized as breakthroughs in regenerative medicine, and Revotek has filed for over 200 patents worldwide.

    More information on Revotek's REVOVAS program is available at http://www.revotek.com.cn/

    Caishen.Co - Primary Data for China Secondary Investment and Stock Markets
    PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a Cision company.

    RELATED NEWS